

CHAMPIONS BIOTECHNOLOGY, INC.  
Form 8-K  
December 16, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 15, 2009**

**CHAMPIONS BIOTECHNOLOGY, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation)

**0-17263**

(Commission File Number)

**52-1401755**

(IRS Employer Identification No.)

**Science and Technology Park at Johns Hopkins**

**855 N. Wolfe Street, Suite 619, Baltimore, MD**

(Address of Principal Executive Offices)

**21205**

(Zip Code)

Registrant's telephone number, including area code: **(410) 369-0365**

**Inapplicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 2.02. Results of Operations and Financial Condition.**

On December 15, 2009, Champions Biotechnology, Inc. (the “**Company**”) announced its results of operations for its fiscal quarter ended October 31, 2009. A copy of the Company’s press release announcing such results dated December 15, 2009 is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission (“**SEC**”) and shall not be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Securities Act of 1933.

**Item 9.01. Financial Statements and Exhibits.**

*(c) Exhibits*

The following exhibits are filed herewith:

Exhibit No.

99.1                    Press Release dated December 15, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CHAMPIONS BIOTECHNOLOGY, INC.**

(Registrant)

Date: December 16, 2009

By: /s/ Douglas D. Burkett

Douglas D. Burkett

President